NCT00054834View on ClinicalTrials.gov

Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma

PHASE1TerminatedINTERVENTIONAL

Enrollment

27

Participants

Timeline

Start Date

March 31, 2003

Conditions

Non-Hodgkins Lymphoma

Interventions

DRUG

hLL2 (epratuzumab)

Trial Locations (2)

Unknown

Fox Chase Cancer Center, Philadelphia

MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT00054834 - Study of 90Y-hLL2 to Treat Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter